Vascular endothelial growth factor inhibitors: Investigational therapies for the treatment of psoriasis

Clinical, Cosmetic and Investigational Dermatology

Volumn 6, Issue , 2013, Pages 233-244

  Weidemann, Anja K ^a   Crawshaw, Ania A ^b   Byrne, Emily ^c   Young, Helen S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Psoriasis; Vascular endothelial growth factor; Vegf; Vegf inhibitor

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BRIVANIB; CAPRESLSA; CEDIRANIB; COAL TAR; CYCLOOXYGENASE 2; CYCLOSPORIN A; INFLIXIMAB; LINIFANIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY G6 31; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NINTEDANIB; PAZOPANIB; PEGAPTANIB; PLINABULIN; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RANIBIZUMAB; RETINOIC ACID; RETINOID; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; V TRAP; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ALOPECIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AUTOIMMUNE DISEASE; BLOOD LEVEL; BLOOD PRESSURE; BREAST CANCER; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; COLON CANCER; COLORECTAL CANCER; CORNEA NEOVASCULARIZATION; CORRELATION ANALYSIS; CYTOLOGY; DIABETIC RETINOPATHY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; EXPERIMENTAL THERAPY; EXUDATIVE MACULAR DEGENERATION; EYE CANCER; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENETIC PREDISPOSITION; GLIOBLASTOMA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LENS DISEASE; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEOVASCULAR GLAUCOMA; NONHUMAN; OFF LABEL DRUG USE; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA TEAR; RETINA VEIN OCCLUSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SKIN EXFOLIATION; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; UVEA MELANOMA; UVEITIS; VITREOUS HEMORRHAGE; WOUND HEALING IMPAIRMENT;

EID: 84884808814     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S35312     Document Type: Review

References (114)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314-320.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-407.
3. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654-662.
4. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
5. Barker JN. The pathophysiology of psoriasis. Lancet. 1991;338(8761): 227-230.
6. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
7. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol. 2012;51(4):389-395; quiz 395.
8. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141-1146.
9. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004;122(1):209-215.
10. Hernández GL, Volpert OV, Iñiguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193(5):607-620.
11. García-Caballero M, Marí-Beffa M, Medina MÁ, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol. 2011; 131(6):1347-1355.
12. Meissner M, Doll M, Hrgovic I, et al. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol. 2011;131(6):1356-1364.
13. Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol. 2006;54(6):1003-1012.
14. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther. 2004;6(4):R326-R334.
15. Deng H, Yan CL, Hu Y, Xu Y, Liao KH. Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed. 2004;20(4):191-199.
16. Akman A, Dicle O, Yilmaz F, Coskun M, Yilmaz E. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed. 2008;24(3):123-127.
17. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012;61(2):47-56.
18. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol. 2004;1(1):39-43.
19. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(5):415-429.
20. Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2011;22(3):199-204.
21. Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34(5):e202-e204.
22. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res. 2007;149(3):103-106.
23. Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J. 2010;16(2):17.
24. Narayanan S, Callis-Duffin K, Batten J, Agarwal N. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010;339(6):580-581.
25. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102(1):161-168.
26. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16): 10931-10934.
27. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65-71.
28. Bianchi E, Scarinci F, Grande C, et al. Immunohistochemical profile of VEGF, TGF-β and PGE2 in human pterygium and normal conjunctiva: experimental study and review of the literature. Int J Immunopathol Pharmacol. 2012;25(3):607-615.
29. Brenchley PE. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol. 2000;121(3):426-429.
30. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
31. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs. 2007;16(1):83-107.
32. Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2003;3(2):95-117.
33. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172(6):1535-1545.
34. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
35. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267(36):26031-26037.
36. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34(12):1785-1788.
37. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380(6573):435-439.
38. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12):1245-1249.
39. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232-1235.
40. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006; 126(2):453-459.
41. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141(6):1054-1060.
42. Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res. 2007;298(10):479-483.
43. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol. 2002;138(6):791-796.
44. Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med. 2002;4(26):1-22.
45. Yano K, Kadoya K, Kajiya K, Hong YK, Detmar M. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol. 2005;152(1):115-121.
46. Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, Fidler IJ. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111(5):864-872.
47. Arbiser JL. Fumarate esters as angiogenesis inhibitors: key to action in psoriasis? J Invest Dermatol. 2011;131(6):1189-1191.
48. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem. 1998;273(34):22128-22135.
49. Brotas AM, Cunha JM, Lago EH, Machado CC, Carneiro SC. Tumor necrosis factor-alpha and the cytokine network in psoriasis. An Bras Dermatol. 2012;87(5):673-681; quiz 682.
50. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57.
51. Korpanty G, Smyth E. Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. Curr Pharm Des. 2012;18(19):2680-2701.
52. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227 Suppl 1:11-20.
53. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012;13(5):247-263.
54. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-4599.
55. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12(3):356-361.
56. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713-718.
57. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 2010;15(1):104-111.
58. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
59. Saeed MU, Gkaragkani E, Ali K. Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol. 2013;6:533-543.
60. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa). 2006;26(8):859-870.
61. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398.
62. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-270.
63. Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol. 2012;6:19-30.
64. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574-6581.
65. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923-926.
66. Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH. Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol. 2012;2012:540-791.
67. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689-2695.
68. Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008;9(3):499-508.
69. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-1934.
70. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714-727.
71. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14(4):378-390.
72. Ribatti D. Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma. Pharmaceuticals. 2010;3:1225-1231.
73. O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173-182.
74. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008;173(1):265-277.
75. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107-113.
76. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337.
77. Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012;7(2):117-125.
78. Velho TR, Kapiteijn E, Jager MJ. New therapeutic agents in uveal melanoma. Anticancer Res. 2012;32(7):2591-2598.
79. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
80. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008;134(2):379.
81. Zhang J, Gold KA, Kim E. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs. 2012;21(9):1417-1426.
82. Zauli G, Voltan R, Tisato V, Secchiero P. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem. 2012;19(28):4875-4884.
83. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140.
84. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186-193.
85. van Heeckeren WJ, Sanborn SL, Narayan A, et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol. 2007; 14(5):468-480.
86. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454-459.
87. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81-87.
88. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273-1279.
89. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356(7):748-9; author reply 749.
90. Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One. 2012;7(8):e42701.
91. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
92. Hutson TE, Bellmunt J, Porta C, et al; Sorafenib TARGET Clinical Trial Group. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010;46(13):2432-2440.
93. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007;29(7):1338-1353.
94. Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013;108(2):311-318.
95. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-2508.
96. Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L. Acute cardiac failure after sunitinib. Ann Oncol. 2008;19(3):597-599.
97. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613-1618.
98. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535-1542.
99. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-5212.
100. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-764.
101. Al'Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol. 1994;130(2):199-203.
102. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23(4):681-694.
103. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233-240.
104. Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol. 2006;155(1):213-214.
105. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol. 2002;147(2):406-407.
106. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol. 2004;84(4):308-309.
107. O'Connor JP, Carano RA, Clamp AR, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res. 2009;15(21):6674-6682.
108. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369-375.
109. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci U S A. 2009;106(50):21264-21269.
110. Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104(4):1048-1057.
111. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998;17(2):155-161.
112. Jung K, Lee D, Lim HS, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem. 2011;286(16):14410-14418.
113. Agosta E, Lazzeri S, Orlandi P, et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics. 2012;13(9):1037-1053.
114. Crawshaw AA, Griffiths CEM, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Invest Drugs. 2012;21:33-43.